{"transactions":[{"id":2743795,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T18:59:28.000Z","date":"2021-04-20","kind":"sale","acquired":false,"shares":19,"price":20.63,"value":391.97,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1301537,"source":{"system":"sec-edgar","filing":"0001209191-21-027623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121027623/doc4.xml","form_type":"4"}},{"id":2743794,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T18:59:28.000Z","date":"2021-04-20","kind":"sale","acquired":false,"shares":21532,"price":20.1,"value":432793.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.61 to $20.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1301556,"source":{"system":"sec-edgar","filing":"0001209191-21-027623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121027623/doc4.xml","form_type":"4"}},{"id":2743793,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T18:59:28.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":4157,"price":21.38,"value":88876.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.87 to $21.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1323088,"source":{"system":"sec-edgar","filing":"0001209191-21-027623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121027623/doc4.xml","form_type":"4"}},{"id":2743792,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T18:59:28.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":9847,"price":20.25,"value":199401.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.87 to $20.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1327245,"source":{"system":"sec-edgar","filing":"0001209191-21-027623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121027623/doc4.xml","form_type":"4"}},{"id":2743791,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T18:59:28.000Z","date":"2021-04-16","kind":"sale","acquired":false,"shares":7870,"price":21.56,"value":169677.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.23 to $21.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1337092,"source":{"system":"sec-edgar","filing":"0001209191-21-027623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121027623/doc4.xml","form_type":"4"}},{"id":2743790,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T18:59:28.000Z","date":"2021-04-16","kind":"sale","acquired":false,"shares":25292,"price":20.84,"value":527085.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $21.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1344962,"source":{"system":"sec-edgar","filing":"0001209191-21-027623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121027623/doc4.xml","form_type":"4"}},{"id":2748200,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T18:57:56.000Z","date":"2021-04-15","kind":"sale","acquired":false,"shares":24818,"price":21.78,"value":540536.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1370254,"source":{"system":"sec-edgar","filing":"0001209191-21-026871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026871/doc4.xml","form_type":"4"}},{"id":2748199,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T18:57:56.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":18938,"price":23.1,"value":437467.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.88 to $23.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1395072,"source":{"system":"sec-edgar","filing":"0001209191-21-026871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026871/doc4.xml","form_type":"4"}},{"id":2748198,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T18:57:56.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":13698,"price":22.38,"value":306561.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1414010,"source":{"system":"sec-edgar","filing":"0001209191-21-026871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026871/doc4.xml","form_type":"4"}},{"id":2748197,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T18:57:56.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":1285,"price":25.18,"value":32356.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 to $25.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1427708,"source":{"system":"sec-edgar","filing":"0001209191-21-026871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026871/doc4.xml","form_type":"4"}},{"id":2748196,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T18:57:56.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":5738,"price":24.4,"value":140007.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1428993,"source":{"system":"sec-edgar","filing":"0001209191-21-026871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026871/doc4.xml","form_type":"4"}},{"id":2748195,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T18:57:56.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":9997,"price":23.35,"value":233429.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.74 to $23.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1434731,"source":{"system":"sec-edgar","filing":"0001209191-21-026871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026871/doc4.xml","form_type":"4"}},{"id":2751057,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T20:33:55.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":100,"price":27.21,"value":2721.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1444728,"source":{"system":"sec-edgar","filing":"0001209191-21-026394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026394/doc4.xml","form_type":"4"}},{"id":2751056,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T20:33:55.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":15728,"price":26.27,"value":413174.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $27.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1444828,"source":{"system":"sec-edgar","filing":"0001209191-21-026394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026394/doc4.xml","form_type":"4"}},{"id":2751055,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T20:33:55.000Z","date":"2021-04-09","kind":"sale","acquired":false,"shares":21660,"price":27.2,"value":589152.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1460556,"source":{"system":"sec-edgar","filing":"0001209191-21-026394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026394/doc4.xml","form_type":"4"}},{"id":2751054,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T20:33:55.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":24816,"price":27.91,"value":692614.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.47 to $28.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1482216,"source":{"system":"sec-edgar","filing":"0001209191-21-026394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026394/doc4.xml","form_type":"4"}},{"id":2751053,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-12T20:33:55.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":38312,"price":27.09,"value":1037872.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1507032,"source":{"system":"sec-edgar","filing":"0001209191-21-026394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121026394/doc4.xml","form_type":"4"}},{"id":3004819,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2020-10-16T15:49:55.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"price":0,"reported_value":2729859.81,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":16.15,"expiration_date":"2022-02-20","underlying":"Common Stock","underlying_shares":169031},"source":{"system":"sec-edgar","filing":"0001209191-20-055041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919120055041/doc4.xml","form_type":"4"}},{"id":3004818,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-16T15:49:55.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":1304563,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1376313},"source":{"system":"sec-edgar","filing":"0001209191-20-055041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919120055041/doc4.xml","form_type":"4"}},{"id":3004817,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T15:49:55.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":169031,"price":16.15,"value":2729850.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1545344,"source":{"system":"sec-edgar","filing":"0001209191-20-055041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919120055041/doc4.xml","form_type":"4"}},{"id":3004816,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T15:49:55.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":1376313,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nextech V Oncology S.C.S, SICA-SIF (\"Nextech V\"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG (\"Nextech AG\"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":1376313,"source":{"system":"sec-edgar","filing":"0001209191-20-055041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919120055041/doc4.xml","form_type":"4"}},{"id":3121588,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T01:00:19.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders."}],"balance_after":12000,"derivative":{"exercise_price":33.57,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-034587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655759/000120919120034587/doc4.xml","form_type":"4"}},{"id":3509792,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-28T21:11:01.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":12923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on May 23, 2019. The shares underlying the award shall vest in full on May 23, 2020 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders."}],"balance_after":12923,"derivative":{"exercise_price":22.06,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":12923},"source":{"system":"sec-edgar","filing":"0000899243-19-014878","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655759/000089924319014878/doc4.xml","form_type":"4"}},{"id":3797771,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-03T21:18:25.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":4491018,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Nextech V Oncology S.C.S., SICAV-SIF. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV-SIF. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a member of the investment committee of Nextech Invest AG and may be deemed to have shared voting and/or investment power over the shares reported hereby. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1381851},"source":{"system":"sec-edgar","filing":"0000899243-18-026069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1655759/000089924318026069/doc4.xml","form_type":"4"}},{"id":3797770,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:18:25.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":1381851,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Nextech V Oncology S.C.S., SICAV-SIF. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV-SIF. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a member of the investment committee of Nextech Invest AG and may be deemed to have shared voting and/or investment power over the shares reported hereby. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":1694351,"source":{"system":"sec-edgar","filing":"0000899243-18-026069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1655759/000089924318026069/doc4.xml","form_type":"4"}},{"id":3797769,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":140147,"kind":"person","name":"Loven Jakob","position":1,"cik":"0001753644","reported_name":"Loven Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:18:25.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of the Issuer's Common Stock that were purchased in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Nextech V Oncology S.C.S., SICAV-SIF. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV-SIF. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a member of the investment committee of Nextech Invest AG and may be deemed to have shared voting and/or investment power over the shares reported hereby. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein."}],"balance_after":312500,"source":{"system":"sec-edgar","filing":"0000899243-18-026069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1655759/000089924318026069/doc4.xml","form_type":"4"}}]}